Cell injection study for type 1 diabetes
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests a new cell injection (CNK-UT009) for adults with type 1 diabetes. The goal is to see if it can help manage blood sugar and reduce insulin needs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 to 65 years
- Diagnosed with autoimmune type 1 diabetes
- Must have certain antibodies in the blood (like GAD or insulin antibodies)
- C-peptide level between 0.2 and a certain amount after a special meal drink
- Good organ function (heart, lungs, liver, kidneys) and no severe infections or bleeding problems
- No active cancer, recent blood clots, or other serious health issues
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment called GNTI-122 for adults recently diagnosed with type 1 diabetes who still make some insulin. It aims to see if the treatment can help protect the cells that produce insulin.
This trial tests a new treatment made from pig pancreatic cells (called OPF-310) that are placed under the skin to help control blood sugar in people with type 1 diabetes. It is for those whose diabetes is difficult to manage and who have dangerous low blood sugar episodes.
This trial is testing a one-time cell treatment (CARC-101C) for people recently diagnosed with type 1 diabetes. The goal is to see if it is safe and can help preserve the body's ability to make some insulin.
This Phase 1 study tests a new immune-system strategy around islet transplantation (or donor bone marrow therapy) to improve control of type 1 diabetes and reduce dangerous low blood sugar. It mainly aims to see if the approach is safe and helpful in people with long-standing, difficult-to-manage diabetes.
This early-stage trial tests a new type of immune cell therapy (CAR-T cells) designed to stop the body's immune system from attacking insulin-producing cells in type 1 diabetes. The goal is to help preserve remaining pancreas function in people with early-stage disease.
This study tests a new medication, MTX228, to see if it can help people with type 1 diabetes who still make some insulin. It may slow the loss of your own insulin production and improve blood sugar control.
Hear when a new Type 1 Diabetes (T1D) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.